Immunopathologic assessment of PTEN expression

Methods in Molecular Biology

Volumn 1388, Issue , 2016, Pages 23-37

  Castillo Martin, Mireia ^a   Thin, Tin Htwe ^a   Lorduy, Ana Collazo ^a   Cordon Cardo, Carlos ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cultured cells; Formalin fixed tissue samples; Fresh frozen tissue samples; Immunofluorescence; Immunohistochemistry; PTEN protocol

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ANTIGEN RETRIEVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; PROCEDURES;

ANIMALS; CYTOLOGICAL TECHNIQUES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PTEN PHOSPHOHYDROLASE;

EID: 84990228162     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3299-3_3     Document Type: Chapter

References (31)

1. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutatedin human brain, breast, and prostate cancer. Science 275(5308):1943-1947
2. Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significanceacross 12 major cancer types. Nature 502(7471):333-339
3. Song MS, Salmena L, PandolfiPP (2012) Thefunctions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283-296
4. Hopkins BD, Fine B, Steinbach N et al (2013) A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 341(6144):399-402
5. Pulido R, Baker SJ, Barata JT et al (2014) A unified nomenclature and amino acid numbering for human PTEN. Sci Signal 7(332), e15
6. Cho H, Herzka T, Zheng W et al (2014) RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov 4(3):318-333
7. Cordon-Cardo C, Kotsianti A, Verbel DA et al (2007) Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117(7):1876-1883
8. Bordeaux J, Welsh A, Agarwal S et al (2010) Antibody validation. Biotechniques 48(3):197-209
9. Sangale Z, Prass C, Carlson A et al (2011) A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 19(2):173-183
10. Djordjevic B, Hennessy BT, Li J et al (2012) Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25(5):699-708
11. Forbes SA, Bhamra G, Bamford S et al (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10 1
12. Weigelt B, Warne PH, Downward J (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30(29):3222-3233
13. Shipitsin M, Small C, Giladi E et al (2014) Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci 12:40
14. Andersson M, Groseclose MR, Deutch AY et al (2008) Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Methods 5(1):101-108
15. Alexandrov T (2012) MALDI imaging mass spectrometry: statistical data analysis and current computational challenges. BMC Bioinformatics 13(Suppl 16):S11
16. Rizzardi AE, Johnson AT, Vogel RI et al (2012) Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 7:42
17. Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology 49(4):411-424
18. Walker RA (2006) Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. Histopathology 49(4):406-410
19. Aytes A, Mitrofanova A, Lefebvre C et al (2014) Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5):638-651
20. Irshad S, Bansal M, Castillo-Martin M et al (2013) A molecular signature predictive of indolent prostate cancer. Sci Transl Med 5(202):202ra122
21. Bononi A, Pinton P (2015) Study of PTEN subcellular localization. Methods 77-78:92-103
22. Lian Z, Di Cristofano A (2005) Class reunion: PTEN joins the nuclear crew. Oncogene 24(50):7394-7400
23. Nguyen HN, Yang JM Jr, Rahdar M et al (2014) A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Oncogene 34:3737-3743
24. Vazquez F, Grossman SR, Takahashi Y et al (2001) Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276(52):48627-48630
25. Trotman LC, Wang X, Alimonti A et al (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128(1):141-156
26. Jiang K, Lawson D, Cohen C et al (2014) Galectin-3 and PTEN expression in pancreatic ductal adenocarcinoma, pancreatic neuroendocrine neoplasms and gastrointestinal tumors on fine-needle aspiration cytology. Acta Cytol 58(3):281-287
27. Mutter GL, Lin MC, Fitzgerald JT et al (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92(11):924-930
28. Foo WC, Rashid A, Wang H et al (2013) Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 44(6):1024-1030
29. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW et al (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6):675-680
30. Tapia O, Riquelme I, Leal P et al (2014) The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 465(1):25-33
31. Garg K, Broaddus RR, Soslow RA et al (2012) Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 31(1):48-56